Health experts say popular weight-loss drugs like Ozempic and Wegovy are safe, but the FDA warns counterfeits are becoming more widespread.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

So, if you are trying to lose weight, you know the importance of including healthy foods in your diet. In the list of healthy foods, nuts are counted as superfoods that contain antioxidant levels ...

As weight loss ... type 2 diabetes. What Is Farxiga? Farxiga is a brand-name medication that contains the active ingredient dapagliflozin. It is not available in generic form. Farxiga is available as ...

Rybelsus (semaglutide ... loss. As well, Rybelsus commonly causes digestive side effects, such as diarrhea, nausea, and vomiting. These side effects may sometimes lead to weight loss. If you have ...

The Edmonton Oilers saw their three-game winning streak come to an end on Thursday (Jan. 30), losing 3-2 to the Detroit Red Wings in a game decided by a shootout at Rogers Place. Edmonton’s Leon ...

The Nevada Gaming Control Board reported football cost online and retail books $2.1 million, the first monthly loss during the NFL regular season since falling $5.3 million short in Nov. 2012.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

GLP-1 agonists mimic the natural hormone glucagon-like peptide ... s not a weight loss medication. Starting dose: 0.25 mg weekly for 4 weeks. Gradually increased to a maximum dose of 2.0 mg ...

An 8-ounce cup of decaf coffee might contain 2-15 milligrams of caffeine. How much caffeine is in your cup of decaf depends on how it's prepared. Additional sweeteners or flavors can increase the ...

Com­pound­ing fa­cil­i­ty ProRx Phar­ma­cy Net­work has re­ceived an FDA warn­ing let­ter over is­sues with its semaglu­tide and tirzepatide pro­duc­tion.